+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glaucoma: Competitive Landscape to 2026

  • PDF Icon


  • 48 Pages
  • December 2018
  • Region: Global
  • GlobalData
  • ID: 4747098
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Glaucoma: Competitive Landscape to 2026


With no new classes of drugs having been developed for the treatment of glaucoma in the last twenty years, the focus of pharmaceutical companies has begun to shift towards the development of glaucoma drugs with novel mechanisms of action (MOAs), and this trend is expected to continue to 2026. The launch of 11 new therapies will drive growth in the glaucoma space, provide more options for patients, and stimulate further competition.

The glaucoma pipeline features 120 drugs across all stages of development, with more than two-thirds of the pipeline drugs being developed in early stage. Small molecules are the focus of drug developers as these constitute more than 68% of the total glaucoma pipeline drugs. According to latest report: ‘Glaucoma: Competitive Landscape to 2026' 11 late-stage drug products will launch in the eight major markets (8MM - US, France, Germany, Italy, Spain, UK, Japan and China) during, or shortly after, the forecast period from 2016 to 2026.

Glaucoma is an established indication, with large numbers of treatments that have become available over the years, and as a result the disease is generally associated with low levels of unmet needs. However, some unmet need does remain in this disease area, with most of these generally considered to be for greater patient compliance.

The importance of a greater compliance in glaucoma is reflected in the late-stage pipeline, which contains several products developed to help meet this unmet need. In particular, there are two SR implants, Ocular Therapeutix's OTX-TP and Allergan's Bimatoprost SR, which will provide a sustained release of drugs directly into the eye, and avoid potential issues of non-compliance associated with topical drugs. These two products, when they will be launched, are expected to have a significant impact on the glaucoma market.

The glaucoma market is highly competitive, heavily genericized and dominated by PGA drugs, particularly by generic latanoprost, which captures the largest patient share of any glaucoma drug throughout the 8MM. However, ample opportunity exists for new treatment options to impact the market, as highlighted by a healthy late-stage clinical pipeline.

Even though the glaucoma market is crowded and increasingly genericized, there are opportunities for products that are able to help address existing unmet needs. The first SR implants for glaucoma are set to launch in 2020, and are expected to improve compliance and convenience of treatment in glaucoma patients. However, all developmental implants currently use a PGA as the active component, meaning there is opportunity for further implants that contain other therapeutic classes as the active ingredient, or even an FDC of multiple drugs.

The report "Glaucoma: Competitive Landscape to 2026", provides an assessment of the pipeline, clinical, and commercial landscape of Glaucoma. It expects new drug approvals to drive Glaucoma market growth over the next decade (2016-2026).

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

  • Commercial Assessment: leading marketed products, current and future players

  • Competitive Landscape: Analysis-key market events (2016-2026).

Reasons to buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the global Glaucoma market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface
1.1 Table of Contents
1.2 Abbreviations
1.3 Related Reports
2. Executive Summary
2.2 Key Findings
2.2 Key Events
3. Introduction
3.1 Report Scope 9-
3.2 Disease Overview and Epidemiology 11-
4. Pipeline Assessment
4.1 Pipeline Overview 15-
4.2 Pipeline Breakdown by Region/Country
4.3 Pipeline Breakdown by Molecule Type and Target
4.4 Drug Review Designations
4.5 Products in Clinical Development 20-
5. Clinical Trial Assessment
5.1 Clinical Trials Overview
5.2 Top Sponsors of Clinical Trials in Glaucoma 24-
5.3 Trial Breakdown by Region
5.4 Therapy Area Perspective
5.5 Enrollment Analytics 28-
6 Commercial Assessment
6.1 Leading Marketed Products
6.2 Current & Future Players
7. Competitive Landscape Analysis (2016-2026)
7.1 Events Classification Overview
7.2 US
7.3 5EU
7.4 Japan and China
8 Appendix
8.1 Sources
8.2 Methodology
8.3 Key Events Included in the Analysis
8.4 About the Authors 43-
8.5 About the Publisher
8.6 Disclaimer

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aerie Pharmaceutical

  • Ocular Therapeutix

  • Allergan

  • Santen Pharmaceutical

  • Neurotech Pharmaeutical

  • Isarna Therapeutics

  • Senju Pharmaceutical

  • Wakamoto Pharmaceutical

  • Envisia Therapeutics

  • Lee’s Pharmaceutical

  • Astellas

  • NicOx

  • Alcon

  • Pfizer

  • Kowa

  • Bausch + Lomb

  • Otsuka Pharmaceutical

  • Merck & Co.

  • InnFocus

  • ForSight VISION5